Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Research & Development (2022 - 2025)

Coeptis Therapeutics Holdings has reported Research & Development over the past 4 years, most recently at $312903.0 for Q4 2025.

  • Quarterly results put Research & Development at $312903.0 for Q4 2025, down 9.01% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (down 45.22% YoY), and the annual figure for FY2025 was $1.3 million, down 45.22%.
  • Research & Development for Q4 2025 was $312903.0 at Coeptis Therapeutics Holdings, down from $587279.0 in the prior quarter.
  • Over the last five years, Research & Development for COEPW hit a ceiling of $5.1 million in Q3 2023 and a floor of $20887.0 in Q3 2022.
  • Median Research & Development over the past 4 years was $398817.0 (2024), compared with a mean of $792140.7.
  • Biggest five-year swings in Research & Development: skyrocketed 24187.54% in 2023 and later plummeted 88.85% in 2025.
  • Coeptis Therapeutics Holdings' Research & Development stood at $20887.0 in 2022, then surged by 4751.57% to $1.0 million in 2023, then plummeted by 66.07% to $343878.0 in 2024, then decreased by 9.01% to $312903.0 in 2025.
  • The last three reported values for Research & Development were $312903.0 (Q4 2025), $587279.0 (Q3 2025), and $290309.0 (Q2 2025) per Business Quant data.